Edition:
United States

Cellular Biomedicine Group Inc (CBMG.OQ)

CBMG.OQ on NASDAQ Stock Exchange Global Market

10.50USD
14 Dec 2017
Change (% chg)

$-0.10 (-0.94%)
Prev Close
$10.60
Open
$10.65
Day's High
$10.70
Day's Low
$10.50
Volume
2,564
Avg. Vol
7,156
52-wk High
$13.75
52-wk Low
$5.15

Summary

Name Age Since Current Position

Terry Belmont

69 2016 Chairman of the Board

Bizuo Liu

50 2016 Chief Executive Officer, Interim Chief Financial Officer, Secretary

Xia Meng

2017 Chief Operating Officer

Yihong Yao

2015 Chief Scientific Officer

Richard Wang

2015 Chief Operation Officer

Zhou Hansheng

2016 Director

Gerardus Hoogland

59 Director

Gang Ji

41 2016 Director

Hansheng Zhou

2016 Non-Executive Director

Chun Kwok Alan Au

42 2014 Independent Director

David Bolocan

51 2013 Independent Director

Nadir Patel

45 2014 Independent Director

Sarah Kelly

Director of Corporate Communications

Biographies

Name Description

Terry Belmont

Mr. Terry A. Belmont is Chairman of the Board of the Company. He was Independent Director of Cellular Biomedicine Group, Inc. Since 2009, Mr. Belmont has overseen UC Irvine Medical Center, the main campus of UC Irvine Health, in Orange, Calif., and its licensed ambulatory facilities in Orange, Irvine, Costa Mesa, Anaheim and Santa Ana. Since his arrival in 2009, Belmont has led several expansion and renovation projects. He helped open the state-of the-art UC Irvine Douglas Hospital and led the development of a patient-centered healing garden and a 7-story clinical laboratory building. Mr. Belmont recently launched a 10-year facility master planning project for facility development at UC Irvine Medical Center and clinics throughout Orange County. Prior to joining UC Irvine Medical Center, Mr. Belmont served as CEO of Long Beach Memorial Medical Center and Miller Children’s Hospital from 2006-2009. He has also served as president and chief executive officer in several entities, including St. Joseph Hospital of Orange, Pacific Health Resources, California Hospital Medical Center and HealthForward. Mr. Belmont received his master’s in public health with a major in hospital administration from UC Berkeley, and a bachelor’s in business from the University of Redlands.

Bizuo Liu

Mr. Bizuo Liu is Chief Executive Officer, Interim Chief Financial Officer, Secretary of Cellular Biomedicine Group, Inc. Most recently Mr. Liu was Director of the Company from February 2013 to January 2014. Since January 2013, Mr. Liu has served as the Corporate Vice President at Alibaba Group, handling Alibaba’s overseas investments. Since joining Alibaba in 2009, Mr. Liu has severed in various positions including Corporate Vice President at B2B corporate investment, corporate finance, and General Manager for a global ecommerce platform. From July 2011 to December 2012, he served as CFO for HiChina, a subsidiary of Alibaba, an internet infrastructure service provider. Prior to joining Alibaba, Mr. Liu spent 19 years at Microsoft Corporation where he served a variety of finance leadership roles. He was the General Manager at Corporate Strategy looking after Microsoft China investment strategy and Microsoft corporate strategic planning process. Mr. Liu was a leader in Microsoft corporate finance organization during the 1990s as Corporate Accounting Director. Mr. Liu earned a B.S. degree in Physics from Suzhou University, Suzhou, PRC and has completed MBA/MIS course work at Seattle Pacific University. Mr. Liu obtained his Washington State CPA certificate in 1992.

Xia Meng

Dr. Xia Meng serves as Chief Operating Officer of the company. Dr. Meng has over 18 years of experiences in biopharmaceutical and biotechnological industries, including research and development, product development, marketing, sales, business and management in both domestic and international companies. She served as Vice President of Wuhan Dangdai Science & Technology Industry Group (“Dangdai”) from June 2016 to June 2017, where she was in charge of international investments and acquisitions. Dangdai is a principal stockholder of the Company and, until her appointment as Chief Operating Officer of the company, Dr. Meng was designated by Dangdai as a board observer of the Company. Dr. Meng previously served as Chief Executive Officer and a director of Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd. from July 2010 to May 2016, where she managed strategies implementation and daily operations. Dr. Meng also worked at Transgene Biopharmaceutical Technology (Shanghai) Co., Ltd. from December 2011 and May 2016 as General Manager and a director, where she managed research and development of clinical integrated translational medicines for cancers and infectious diseases. From June 2004 to May 2016, Dr. Meng held various positions at bioMérieux Shanghai Co., Ltd., including Scientific Director, Asia Pacific Regional Business Manager and Consultant of the Medical Affairs and R&D Department. While at bioMérieux, Dr. Meng managed the company’s oncology research and development activities and related strategic partnerships in the Asia Pacific region. Transgene and bioMerieux are sister companies under the group of Institut Merieux. Prior to bioMérieux, she served as a director of Shanghai Sunway Biotech Co., Ltd.’s Research Department and a Senior Scientist in the Beijing R&D Center of Novo Nordisk.

Yihong Yao

Dr. Yihong Yao., Ph.D., B.S. is Chief Scientific Officer of Cellular Biomedicine Group Inc. Dr. Yao brings nearly twenty years of experience in the life sciences industry and academia with strong expertise in clinical biomarker discovery and development, strategy and personalized medicine. Dr. Yao received his B.S. degree in Biochemistry from the Department of Biochemistry, Fu Dan University, Shanghai, China, a Master's Degree in bioinformatics from Boston University and his Ph.D. in Molecular Biology & Biochemistry from the Department of Biochemistry, University of Kansas, Lawrence, Kansas, USA. He completed his Postdoctoral Fellowship at Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA. In addition to his strong academic background, he has over fifteen years of professional experience with pharmaceutical and biotechnology companies including MedImmune biologics research and development arm of AstraZeneca, and Abbott Bioresearch Center. Dr. Yao is the co-inventor of twenty-six filed patents relating to tumor classification, degenerative muscle disease and autoimmune disease diagnostics and treatment. He has published over sixty papers in translational science peer-reviewed journals and has authored or co-authored two books on the subjects of inflammatory and autoimmune diseases and genomic biomarkers. Dr. Yao is a frequently invited speaker and panelist for many international conferences on biomarkers, personalized medicine, miRNA, rheumatology and oncology.

Richard Wang

Dr. Richard L. Wang, Ph.D., MBA, PMP is Chief Operation Officer of the Company. Mr. Wang held the position of senior site leader of GSK R&D in Shanghai, China, since 2013, and also held the position of Senior Director and Head of Operations of GSK R&D since 2011. Mr. Wang has been an experienced leader, manager and scientist in pharmaceutical R&D organizations of several multinational companies both in the US and latest in China for the past 21 years. From 2007 to 2011, Mr. Wang was the Director, Head of Strategic Alliance (Asia), and Portfolio and Operation Management of Innovation Center China & Global Oncology, AstraZeneca Global R&D in Shanghai, China. From 2004 to 2007, Mr. Wang was Associate Director, Discovery Portfolio and Early Development Project Management, R&D Operations Pharmaceutical Research Institute, Bristol-Myers Squibb, in Wallingford, Connecticut. He holds a bachelor’s degree in Cell Biology from University of Science & Technology of China, a PhD in Molecular Biology from University of Maryland, Baltimore, and an MBA from Xavier University.

Zhou Hansheng

Dr. Zhou Hansheng is Director of the Company. He currently serves as Chief Executive Officer of Wuhan Dangdai Science & Technology Industries (Group) Co., Ltd, a China-based privately held conglomerate with a substantial medical and pharmaceutical portfolio in China, including the Hong Kong subsidiary Dangdai International Group Co., Limited, which is a major shareholder of CBMG. He previously served as the CFO and Managing Director of Wuhan Humanwell Healthcare Group Co., Ltd. With a bachelor's degree in cell biology and a master's degree in animal physiology, Dr. Zhou earned his Ph.D. in applied chemistry from the Beijing Institute of Technology.

Gerardus Hoogland

Mr. Gerardus A. Hoogland is Director of Cellular Biomedicine Group, Inc. Since October 2013, Mr. Hoogland has served as a director of Cytespace Pvt, Ltd, a clinical research site solution organization located in India. Since July 2013, he has served as Chief Executive Officer of HealthCrest AG, an investment and consulting company based in Zug, Switzerland. Prior to joining HealthCrest, Mr. Hoogland was the Executive Director and board member of Litha Healthcare Ltd., a healthcare company listed on Johannesburg Stock Exchange from July 2012 to July 2013. In 1997, Mr. Hoogland founded Pharmaplan Pty Ltd., a premier specialty pharmaceutical company located in South Africa, and was the company’s Chief Executive Officer from 1997 to July 2012. Mr. Hoogland received his Medical Doctor degree from University of Amsterdam, his Propeduse Law degree from Eramus Universiteit, and his Mater of Business Administration degree from Institute d’Administration des Affaries (INSEAD).

Gang Ji

Mr. Gang Ji serves as Director of the Company effective November 11, 2016. Mr. Ji joined Ant Financial in January 2016 as Vice President. Mr. Ji is responsible for the global strategic investments for Ant Financial and has sixteen years of experience in investment and more than eight years of experience in the internet industry. Before joining Ant Financial, he served Alibaba Group as Vice President, where he was responsible for strategic investment for seven years. Prior to Alibaba, Mr. Ji worked for several venture capital funds and was an auditor of KPMG. He is a director of the publicly listed company Asia Game Technology Ltd (HKEX:8279) as well as several private technology companies. He holds a bachelor's degree in international business management from University of International Business and Economics (Beijing).

Hansheng Zhou

Dr. Hansheng Zhou is Non-Executive Director of the Company. Dr. Zhou is a well-respected and seasoned executive with over 28 years of experience in the science and technology industries in China. He currently serves as Chief Executive Officer and Chairman of Wuhan Dangdai Science & Technology Industries Group Co., Ltd. (“Wuhan Dangdai”), a China based privately held conglomerate with a substantial medical and pharmaceutical portfolio in China. Dr. Zhou previously served as Chief Financial Officer and Managing Director of Wuhan Humanwell Healthcare Group Co., Ltd. He holds a bachelor’s degree in Cell Biology and masters in Animal Biology from Wuhan University and has also earned his PhD degree in Applied Chemistry from Beijing Institute of Technology.

Chun Kwok Alan Au

Mr. Chun Kwok Alan Au is Independent Director of Cellular Biomedicine Group, Inc. Between 2011 and 2012, Alan was Head of Asia Healthcare Investment Banking of Deutsche Bank Group, advising healthcare IPOs and M&A in the region. Prior to that, he was Executive Director at JAFCO Asia Investment Group, responsible for healthcare investments in China from 2008 to 2010, and Investment Director at Morningside Group, responsible for healthcare investments in Asia from 2000 to 2005. From 1995 to 1999, Mr. Au worked at KPMG and KPMG Corporate Finance Ltd., responsible for regional M&A transactions and financial advisory services. Alan is a Certified Public Accountant in the U.S. and holds the Chartered Financial Analyst (CFA) designation. He is an associate member of the Hong Kong Institute of Financial Analysts and member of the American Institute of Certified Public Accountants. Alan received his Bachelor's degree in Psychology from the Chinese University of Hong Kong, and a Master's degree in Management from Columbia Business School in New York.

David Bolocan

Mr. David Bolocan is an Independent Director of Cellular Biomedicine Group, Inc. Mr. Bolocan is currently a managing director for Argus Information and Advisory Services, LLC and leads the Retail Banking Solutions group which includes the Deposit Accounts Payment Study and retail banking client delivery groups. Prior to joining Argus Mr. Bolocan held senior executive roles at SunTrust (Head of Consumer Deposit Products), JPM Chase (Head of Small Business Credit Products, Pricing and Analytics), MBNA/Bank of America (CMO of Small Business Lending), and consulting positions at Mercer Management Consulting, Mitchell Madison Group, and AlixPartners. Mr. Bolocan received an MS/MBA from the MIT Sloan School of Management and a BA from Harvard University in Computer Science and Economics. In considering Mr. Bolocan’s eligibility to serve on the Board, the Board considered Mr. Bolocan’s extensive experience in the management of large complex businesses, as well as his financial expertise.

Nadir Patel

Mr. Nadir Patel is an Independent Director of Cellular Biomedicine Group, Inc. Since July 2011 Mr. Patel has been serving as Assistant Deputy Minister, Corporate Planning, Finance and Information Technology, and Chief Financial Officer for Canada’s Department of Foreign Affairs, Trade and Development, which includes the responsibilities of strategic planning, finance, information management and technology, risk management and performance. Previously, from April 2009 to July 2011, Mr. Patel served as Canada’s Consul General in Shanghai, promoting trade and investment between Canada and China. From summer 2007 to April 2009, he served as Chief Air Negotiator for Canada's Department of Foreign Affairs, Trade and Development, negotiating trade agreements and treaties on behalf of the Canadian government. Mr. Patel also serves on the Board of Governors of the International Development Research Centre (and on its Audit and Finance Committee), as well as the Ottawa Advisory Board of Wilfrid Laurier University’s School of Business and Economics. He has a Master of Business Administration (MBA) from New York University’s Stern School of Business, the London School of Economics and Political Science, and the HEC Paris School of Management.

Sarah Kelly